title: Induction therapy of loco-regional non-small-cell lung cancer with reliable response and low toxicity (low dose radiotherapy sensitizes tumor to subsequent chemotherapy?).
abstract: BACKGROUND
  For the induction therapy of non-small-cell lung cancer, we need to look for a regimen which produces a reliable high response rate with a low treatment related morbidity and mortality.
  
  
  METHODS
  Patients in clinical stages IB, IIA and B, IIIA and B received a course of therapy with 20Gy of radiation in 2 weeks. This was followed by two courses of chemotherapy consisting of paclitaxel 180mg/m(2), cisplatin 45mg/m(2), and ifosfamide 1000mg/m(2). Two to 3 weeks after chemotherapy, the patients were re-evaluated and, if suitable, underwent surgical therapy.
  
  
  RESULTS
  A total of 35 patients were entered into the study. The overall response rate was 82.86% (95% confidence interval, 66.35-94.5%). Complete response (CR) was 20% (95% confidence interval, 8.44-36.94%). Twenty-five patients had surgical resection. Subsequently 18 patients received completion radiotherapy of additional 45Gy. The median follow up is 30 months. In 12 patients with stages IB, IIA and B, the median survival was 61 months, and 5-year survival was 55%. In 23 patients with stages IIIA and B, the median survival was 26 months, and 5-year survival was 9.5%. There was 1 patient with Grade 4 and 13 patients with Grade 3 leukopenia, and half of them received granulocyte colony stimulating factor. By the completion radiotherapy, 6 out of 18 patients had less than Grade 2 esophagitis. Five patients had Grade 2 radiation pneumonitis and one Grade 5 (one mortality). There was no postoperative death. The survival results were comparable to those reported recently by others, however the regimen produced a high response rate with low treatment related morbidity/mortality.
  
  
  CONCLUSIONS
  It is a suitable regimen for induction therapy to include earlier stage resectable non-small-cell lung cancers.
authors.affiliation: Millard Fillmore Hospital, Department of Surgery, State University of New York at Buffalo, Buffalo, NY, United States. htakita007@aol.com
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takita
authors.forename: Kyu H
authors.initials: KH
authors.lastname: Shin
authors.forename: Andrew Y
authors.initials: AY
authors.lastname: Soh
authors.forename: Won S
authors.initials: WS
authors.lastname: Yi
authors.forename: Greg
authors.initials: G
authors.lastname: Wilding
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D013902:Radiography, Thoracic; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents